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ABSTRACT: A new class of nontoxic triaryl benzimidazole compounds, derived from
existing classes of DNA minor groove binders, were designed, synthesized, and evaluated for
their antibacterial activity against multidrug resistant (MDR) Gram-positive and Gram-
negative species. Molecular modeling experiments suggest that the newly synthesized class
cannot be accommodated within the minor groove of DNA due to a change in the shape of
the molecules. Compounds 8, 13, and 14 were found to be the most active of the series, with
MICs in the range of 0.5−4 μg/mL against the MDR Staphylococci and Enterococci species.
Compound 13 showed moderate activity against the MDR Gram-negative strains, with MICs
in the range of 16−32 μg/mL. Active compounds showed a bactericidal mode of action, and a
mechanistic study suggested the inhibition of bacterial gyrase as the mechanism of action
(MOA) of this chemical class. The MOA was further supported by the molecular modeling
study.
■ INTRODUCTION
Antibiotic resistance is a major global issue. The rapid spread of
resistance, along with the so-called “discovery void” of new
classes of antibiotics, brought the prospect of a “post-antibiotic
era”, where limited therapeutic alternatives are available for the
treatment of infections caused by multidrug resistant (MDR)
pathogens.1,2 Increasing occurrence of infection caused by
MDR strains belonging to the ESKAPE group of pathogens is a
matter of great concern across the world.3,4 According to WHO
and ECDC reports, diseases related to MDR pathogens are
responsible for 25000 and 23000 deaths a year in Europe and
the U.S., respectively. Those values are predicted to increase to
10 million deaths a year in 2050 if the surge in antimicrobial
resistance (AMR) is left unchecked.5 This phenomenon is
caused primarily by the lack of discovery of new classes of
antibiotics in the last 30 years and the rapid increase in
resistance to existing classes of antibiotic.6 The last classes of
antibacterial drugs with activity against Gram-positive bacteria
(mutilins, lipopeptides, and oxazolidinones) were introduced in
the 2000s, but their discovery goes as far back as the 1980s
while the last broad spectrum antibiotic class, quinolones, was
introduced almost 50 years ago in 1964.6,7 This extended
period, often described as a “discovery void”, reﬂects the failure
of the antibacterial drug discovery processes.6,8,9 The target-
based, genomic-driven approach, while presenting enormous
advantages in terms of rationalization of the research and
reduced costs, failed in ﬁnding scaﬀolds belonging to new
chemical classes with antibacterial activity.10 This is due to the
fact that in most cases, the translation of compounds identiﬁed
through cell-free HTS assay into candidates with in vitro and
ultimately in vivo eﬃcacy was unsuccessful. This failure could
be partly due to either the target not being suﬃciently validated
or the inability of the compounds to penetrate bacteria and
partly due to their inability to overcome the resistance
mechanisms that are commonly associated with MDR bacteria.
A solution proposed to overcome this impasse in the
antibacterial drug discovery process can be found in the
expansion of the chemical space of antibacterial drugs.8 The
discovery of new scaﬀolds derived from natural sources or
chemical synthesis could open the way to alternative classes of
antibiotics with new mechanisms of action. Several results
indicated benzofused rings, especially benzimidazole, as
promising moieties to design novel scaﬀolds with antibacterial
activity.11−14 According to the literature, several pharmaco-
logical activities (such as antibacterial, anticancer, and anti-
inﬂammatory) are attributed to benzimidazole derivatives.15,16
This wide range of activity is attributed to the peculiar chemical
features of azole rings, which are able to interact in a
noncovalent way with a range of targets due to the presence
of an electron-rich aromatic system and heteroatoms.17,18
Diﬀerent derivatives of the bis-benzimidazole ﬂuorescent dye 4-
(6-(4-methylpiperazin-1-yl)-1H,3′H-[2,5′-bibenzo[d]imidazol]-
2′-yl)phenol (Hoechst 33258, Figure 1) have shown notable
antibacterial activity against MRSA and VRE.19 The Hoechst
series of dyes is a group of molecules widely used to stain DNA
sequences in biology due to their ability to bind to AT-rich
sequences in the minor groove of DNA. By simply changing the
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conﬁguration of the binding of the two sequential benzimida-
zoles units from head to tail to symmetric head to head, a new
series of derivatives with increased anticancer and antibacterial
activity against the MRSA and VRE strains has been developed.
Recently, compounds belonging to this class have been
reported to be active against MRSA and VRE pathogenic
strains, with MICs in the range between 0.06 and 8 μg/mL and
an example is compound 1 (compound A, Figure 1).20 This
process also lead to the discovery of 2,2′-di(pyridin-4-yl)-
1H,3′H-5,5′-bibenzo[d]imidazole (SMT-19969, Figure 1), a
nonabsorbable agent for the treatment of Gram-positive
Clostridium diﬃcile infections that recently entered phase II
clinical trials.21 Other research groups focused their attention
on the Hoechst derivatives by designing a series of diamidine
dicationic molecules, in which the two benzimidazole units are
separated by a symmetric diaryl spacer. The most interesting
molecule in this class was represented by compound 2 (DB-
325, Figure 1); along with its derivatives, it presented good
antibacterial activity against MRSA and VRE pathogenic agents
with MICs between 0.06 and 1 μg/mL.22−24 Although diﬀerent
mechanisms of action that are able to explain the activity of
these molecules have been proposed,25,26 a possible major issue
for this series of derivatives is related to their ability to bind to
the minor groove of DNA. This could cause unwanted
eukaryotic toxicity which would be undesirable, especially for
compounds that are only active against Gram-positive strains
for which limited, but safer, therapeutic alternatives are still
available. For this reason, we designed a new triaryl
benzimidazole scaﬀold with the aim of developing a new,
safer antibacterial agent against multidrug resistant MRSA and
VRE strains. In this article, we report the design, molecular
modeling study, synthesis, and microbiological proﬁle evalua-
tion of this new class of compounds.
■ RESULTS AND DISCUSSION
Design of Compounds and Molecular Modeling. We
designed a new triaryl benzimidazole scaﬀold characterized by
its reduced aﬃnity toward the minor groove of DNA with the
aim of improving the cytotoxicity proﬁle against eukaryotic cell
lines. The new scaﬀold (Figure 2) presents a central
biarylpyridino-phenyl spacer linked to two benzimidazole
units. The central linker in the bis-amidine and bis-
benzimidazole compounds has been studied by diﬀerent
research groups, and the biphenyl spacers have been shown
to reduce the interaction of molecules with the minor groove of
DNA compared to alkyl and alkenyl spacers.27 To change the
shape of the molecule, one benzimidazole moiety is directly
linked through a C−N bond to the pyridine ring, while the
other one is connected through an amide linker to the phenyl
ring. Moreover, to disrupt the linearity of the molecule and
conferring a diﬀerent three-dimensional shape compared to
previously reported molecules, the benzimidazole moieties are
linked in a nonsymmetric way to the central spacer. The
scaﬀold is then completed by a protonable tertiary aminic
lateral chain that has been reported to be important in
conferring antibacterial activity against MRSA and VRE
strains.20
To prove the hypothesis that the new scaﬀold has reduced
aﬃnity to the minor groove of DNA, in comparison with
previously reported bis-benzimidazole antibacterial molecules,
we performed molecular modeling of the selected compounds
against diﬀerent sequences of DNA. Compounds 1, 2, and the
newly designed scaﬀold completed by a diethylamino tail
(compound 8) underwent molecular docking against three
diﬀerent sequences of DNA (Figure 3A,B). The selected
sequences represent a mixed sequence, a GC-rich sequence and
an AT-rich sequence and are reported in Table 1 along with the
result of the docking experiment expressed in predicted aﬃnity
(kcal/mol) for the DNA sequences. The experiment indicates
that the literature compounds bind preferentially to the minor
groove of DNA through a network of conventional hydrogen
bonds and carbon−hydrogen bonds between the hydrogen rich
molecules and the DNA sequences, with some additionally
hydrophobic interaction reported for compound 8. The
behavior is consistent with the one reported for Hoechst
derivatives, with a higher predicted aﬃnity for the AT-rich
DNA sequences.28 The newly designed scaﬀold presents a
lower predicted aﬃnity for the minor groove of DNA compared
to the examples from the literature, indicating that the scaﬀold
could not be accommodated favorably within the minor groove.
According to the best docking pose reported in Figure 3 for the
random DNA sequence, the second benzimidazole moiety of
the newly designed scaﬀold stays outside the minor groove of
DNA. This behavior is not consistent to the one shown by
examples from the literature that bind well with the minor
groove of DNA. The modeling study indicated that the
introduction of the amide linkage disrupted the isohelicity of
the newly designed molecules. We hypothesized that this
inability to bind to the minor groove of DNA would result in
loss of eukaryotic cell toxicity which has previously prevented
further development of bisbenzimidazoles and Hoechst
derivatives as antibacterial agents.
Synthesis and Preliminary SAR. A new synthetic route
was designed for the synthesis of the novel series of compounds
by taking into account the commercial availability of building
Figure 1. Structure of previously synthesized bis-benzimidazole
compounds with antibacterial activity.
Figure 2. General structure of newly designed triaryl benzimidazole
class of compounds.
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blocks (Scheme 1). A retrosynthetic disconnection approach
allowed us to identify the N-pyridyl-benzimidazole moiety as a
key intermediate for the synthesis of the desired compound.
The process started with an aromatic nucleophilic substitution
of 2-amino-5-bromopyridine on methyl-(3-nitro-4-ﬂuoro)-
phenylcarboxylate. The reaction was carried out in THF,
using NaH as a base. In the next step, we used Raney nickel as a
catalyst in a H2 atmosphere (4 atm.) to reduce the nitro group
of 3, thereby obtaining a rapid and complete conversion to the
aniline derivative 5. The formation of the N-pyridyl-
benzimidazole intermediate 5 was achieved by simply reﬂuxing
4 in THF in the presence of methyl orthoacetate and p-
toluenesulfonic acid. Compound 6 was obtained via a Suzuki
coupling reaction with 3-aminophenylboronic acid using
tetrakis(triphenyl)palladium (0) in the presence of K2CO3 as
a catalytic system. The aniline derivative 6 was subsequently
coupled to 2-methyl-1H-benzimidazole-5-carboxylic acid to
give compound 7, using HBTU/DIPEA as coupling reagents.
For the synthesis of 8, compound 7 was ﬁrst hydrolyzed in an
aqueous basic condition to the corresponding carboxylic acid
that was coupled to dimethylaminoethylamine, giving the ﬁnal
product that was synthesized as a proof of principle of our idea.
Figure 3. (A,B) Molecular model showing literature compounds 1 and 2 ﬁts well with the DNA minor groove of a random sequence, while the
designed ligand 8 cannot be accommodated within the DNA minor groove (A). Details of the interaction of the compounds within the minor groove
of DNA (B).
Table 1. Molecular Docking Experiment Showing Aﬃnity of Literature Compounds and Newly Designed Compound 8 against
DNA Sequences
aﬃnity to diﬀerent DNA sequences (kcal/mol)
random seq AT-rich seq GC-rich seq
Ligand 5′-TAGCTAGCTAGCTAGCG-3′ 5′-TATATAAATATATATAT-3′ 5′-GCGCGCGCGCGGCGCGC-3′
1 −11.0 −12.3 −10.5
2 −11.4 −11.9 −12.0
8 −10.2 −10.4 −10.0
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Also, in this case, the HBTU/DIPEA coupling system was used
for the formation of the amide bond.
Compound 8 was tested for its microbiological activity
against VRE-12201 and EMRSA-15 (HO 5096 0412) strains,
resulting in activity with an MIC of 1 and 2 μg/mL, respectively
(Table 2). These results showed that the newly designed triaryl
benzimidazole scaﬀold possesses antibacterial activity and could
be considered as an ideal starting point for medicinal chemistry
optimization of the series. To proceed with a systematic
exploration of the diﬀerent components of the molecule, we
initially focused on possible modiﬁcations which did not change
the central triaryl benzimidazole scaﬀold. Initially, we
substituted the dimethylaminoethyl tail with other tertiary
aminic tails that diﬀer in their shape or carbon chain length
(Scheme 1, compound 8−14). The importance of a protonable
chemical moiety in antibacterial drugs has been investigated in
diﬀerent studies.29,30 Particularly, previous research focused
their attention on the pKa of the selected moieties, with weak
bases found to be more eﬀective in conferring antibacterial
activity to the molecules by providing better penetration
through the bacterial cell wall.31
These modiﬁcations caused a loss of antibacterial activity
with MIC values between 64 and >128 μg/mL for the strains
VRE-12201 and EMRSA-15 (Table 2). Compounds 13 and 14
with the same dimethylamino substitution with longer carbon
chains (3-carbon and 4-carbon, respectively), showed improved
antibacterial activities with MICs of 0.25 and 0.5 μg/mL for
compound 13 and 0.25 and 1 mg/mL for compound 14,
respectively. These two synthesized compounds showed
notably superior activity compared to the 2-carbon tail
analogue, with antibacterial activity comparable to the bis-
benzimidazole compounds reported by Moreira and co-
workers.20 This result demonstrated the importance of the
dimethyl amino substitution pattern on the tertiary aminic tail
for antibacterial activity. A conﬁrmation of the importance of
the protonable moiety was shown by the lack of antibacterial
activity shown by intermediate 7, a direct analogue of
compound 13 without the tertiary aminic tail.
With the aim of improving the activity of 13, we synthesized
compound 17 (Scheme 2) in which an additional dimethyla-
minopropyl tail is added in position 2 of the benzimidazole ring
attached to the central triaryl scaﬀold. Position 2 of the
benzimidazole ring can be modiﬁed through simple synthetic
steps involving the condensation of the diaminobenzoate
derivative with carbonyl compounds. The synthesis of the
required building block 15 was achieved by an MW-assisted
condensation reaction between methyl 3,4-diaminobenzoate
and the 4-(dimethylamino)butanoic acid, using propylphos-
phonic anhydride (T3P) as condensing agent. The reaction
allowed the synthesis of 15 with a good yield without the
formation of byproducts. The building block obtained was then
hydrolyzed in a basic environment to the corresponding
carboxylic acid and coupled to 6, giving 16. The ﬁnal step
involved the hydrolysis of the methyl ester and the sequential
Scheme 1. Synthetic Procedures and Reagents for Compounds 8−14a
aReagents and conditions: (a) NaH 60% mineral oil dispersion, THF at 0 °C then 25 °C, 15 h; (b) Raney nickel, DCM/MeOH, H2 (4 atm), 1 h; (c)
trimethyl orthoacetate, p-TsOH, THF, reﬂux, 15 h; (d) 3-aminophenylboronic acid, tetrakis(triphenyl)palladium(0), K2CO3, THF, reﬂux, 6 h; (e) 2-
methyl-1H-benzimidazole-5-carboxylic acid, HBTU, DIPE, DMF, 50 °C, 2 days; (f) NaOH aq solution, MeOH, 25 °C, 15 h then amine, HBTU,
DIPEA, DMF, 25 °C, 2 h.
Table 2. Antibacterial Activity of the Synthesized
Compounds against MDR VRE and MRSA Strains
MIC (μg/mL)
compd VRE NCTC 12201 MRSA EMRSA-15
7 >32 >32
8 1 2
9 >128 >128
10 64 >128
11 >128 >128
12 >128 >128
13 0.25 0.5
14 0.25 1
16 >128 >128
17 64 >128
18 >128 >128
19 >128 >128
21 >128 >128
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coupling to the dimethylaminopropyl tail to give 17. The
compound was tested for its antibacterial activity; it showed
partial activity (MIC of 64 μg/mL) against the VRE-12201
strain (Table 2). The addition of a second tertiary aminic tail
caused no improvement in the antibacterial activity, contrary to
what was observed in the series of compounds related to 2,
where the deletion of one of the two amidine protonable
moieties diminished the antibacterial activity against Gram-
positive strains.
To verify the importance of the structural constituents of 13,
we synthesized compounds 18 and 19 (Scheme 3). Together
with compound 7, they represent all the possible fragments of
the most active molecule 13. The antibacterial screening
showed no antibacterial activity for the tested molecules against
VRE-12201 and EMRSA-15, revealing the importance of all the
moieties constituting compounds 13 (Table 2).
The importance of the second benzimidazole moiety linked
through amide bond to the triaryl scaﬀold was evaluated with
the synthesis of compound 21 (Scheme 4), in which the azole
fused ring was substituted by a simple benzene ring.
Compound 21 did not show activity against VRE-12201 and
EMRSA-15 strains, conﬁrming the role of benzimidazole ring in
conferring antibacterial activity for this class of molecules.
Compounds having an MIC ≤ 64 μg/mL were screened
against the extended panel of Gram-positive bacteria in order to
verify the antibacterial activity of the selected molecules (Table
3). Compounds 13 and 14 were found to be most active
molecule in this chemical series, with MIC values between 0.25
and 2 μg/mL for both MRSA and VRE strains with activity
comparable or better compared to vancomycin, amoxicillin, and
levoﬂoxacin (Table 3). Good activity was also shown by
compound 8, however, this activity was 4-fold less than 13.
Compound 10 was inactive against all the strains tested, apart
from VRE-12201. Compound 17 showed partial activity against
VRE strains, with an MIC between 32 and 64 μg/mL, but
showed no activity against S. aureus strains. Interestingly, the
most active compounds (8, 13, and 14) showed no eukaryotic
toxicity in the MTT test against HeLa cell lines at a
concentration of 25 μM. The concentration tested is between
30 and 60 times the MIC for compounds 13 and 14, suggesting
an adequate selectivity index between the eukaryotic and
prokaryotic cells’ toxicity (Table 3).
To further test our hypothesis that DNA binding is
associated with increased eukaryotic toxicity, we designed and
then synthesized compound 24. This new molecule is
Scheme 2. Synthetic Procedures and Reagents for Compound 17a
aReagents and conditions: (a) T3P, DIPEA, MW, 160 °C, 40 min; (b) NaOH aq solution, MeOH, 25 °C, 15 h then 6, HBTU, DIPEA, DMF, 25 °C,
2 days; (c) NaOH aq solution, MeOH, 25 °C, 15 h then dimethylaminopropylamina, HBTU, DIPEA, DMF, 25 °C, 2 h.
Scheme 3. Synthetic Procedures and Reagents for
Compound 18−19a
aReagents and conditions: (a) NaOH aq solution, MeOH, 25 °C, 15 h
then dimethylaminopropylamine, HBTU, DIPEA, DMF, 25 °C, 2 h.
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Scheme 4. Synthetic Procedures and Reagents for Compound 21a
aReagents and conditions: (a) benzoic acid, HBTU, DIPEA, DMF, 25 °C 15 h; (b) NaOH aq solution, MeOH, 25 °C, 15 h then
dimethylisopropylamine, HBTU, DIPEA, DMF, 25 °C, 2 h.
Table 3. Antibacterial Activity of Compounds 8, 10, 13, 14, 17, and 24 against the Extended Panel of Gram-Positive Bacteria
and Their Toxicity against the Eukaryotic HeLa Cell Line
Gram-positive strains MIC (μg/mL)
VRE VSE MRSA MSSA
compd NCTC 12201 NCTC 12204 NCTC 775 EMRSA 15 EMRSA 16 (MRSA 252) ATCC 9144 % viability in HeLa cells (MTT test 25 μM)
8 1 2 4 2 8 2 >98
10 64 >128 >128 >128 >32 16. >98
13 0.25 0.5 0.5 0.5 2 0.25 >98
14 0.25 ≤0.125 0.5 1 2 0.5 >98
17 32 64 >128 >128 >128 >128 39
24 64 64 64 >128 >128 >128 62
vancomycin >128 >128 1 2 2 0.5
amoxicillin 0.5 16 0.5 128 >128 1
levoﬂoxacin 1 0.5 1 8 8 0.12
Scheme 5. Synthetic Procedures and Reagents for Compound 24a
aReagents and conditions: (a) HBr aq solution, 0 °C, 10 min then NaNO2, CuBr, 50 °C; (b) 5-benzimidazole boronic acid,
tetrakis(triphenyl)palladium(0), 1 MW irradiation, 150 °C, 15 min; (c) NaOH aq solution, MeOH, 25 °C, 15 h then dimethylaminopropylamine,
HBTU, DIPEA, DMF, 25 °C, 2 h.
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characterized by the presence of a direct C−C bond between
the triaryl benzimidazole scaﬀold and the second benzimidazole
moiety. The deletion of the amide bond led to a new tetra-aryl
scaﬀold, which resulted in less ﬂexibility and shape similarities
to previous classes of bis-benzimidazole molecules. This was
conﬁrmed by molecular docking experiments of the new
compound that were realized on diﬀerent DNA sequences. The
best resulting docking poses (Supporting Information, Figure
S1) showed that the compound binds well to the minor groove
of DNA, with a binding mode comparable to those predicted
for previously reported examples; this was conﬁrmed by
comparing the estimated aﬃnity values with DNA sequences
(Supporting Information, Table S2). Synthetically, the con-
strained tetra-aryl compound 24 was obtained by subjecting the
intermediate 6 to a Sandmeyer-type reaction to obtain the aryl
halide 22. The low yield of the reaction was due to the
simultaneous hydrolysis of the ester moiety caused by strong
acidic conditions, as veriﬁed by the recovery of the
corresponding acid derivative in the reaction mixture. A Suzuki
coupling reaction gave the tetra-aryl scaﬀold 23, which was then
hydrolyzed and coupled with the dimethylaminopropyl tail in
order to give the ﬁnal compound 24 (Scheme 5). The new
tetra-aryl derivative showed reduced antibacterial activity, with
an MIC value of 64 μg/mL against the strain VRE-12201
(Table 3). In addition, the compound was observed to be more
toxic in comparison with its analogue 13, suggesting a good
relationship between the binding mode of tetra-aryl compounds
in the minor groove DNA and their eukaryotic toxicity.
Evaluation of DNA Binding Ability of the Synthesized
Compounds. The ability of compounds 8, 13, and 14 to bind
and stabilize the DNA was evaluated using a FRET-based DNA
melting assay. The compounds were tested using an AT-rich
(FAM-GCT-ATA-TAA-ATA-TAT-ATA-TTT-TAT-ATA-
TAT-ATT-TAT-ATA-GC-TAMRA) ﬂuorophore-labeled oligo-
nucleotide sequence. Netropsin, a known DNA minor groove
binder, was used as a positive control. The result of the assay is
reported in Table 4. Compounds 8, 13, and 14 did not stabilize
the DNA sequence, with ΔTm values <1 C° at 1 μM
concentration (drug:DNA ratio 5:1), while netropsin showed
a signiﬁcant 16.5 °C stabilization at 1 μM. Compound 13 and 8
showed weak DNA stabilization at 5 μM concentration
(drug:DNA ratio 25:1), with 2.1 and 0.9 °C stabilization,
respectively, while Netropsin stabilized the DNA by 22.2 °C.
Compound 14 with the 4-carbon tail did not stabilize the DNA
even at 5 μM concentration with only 0.6 °C stabilization at
25:1 drug:DNA ratio. The result supports the molecular
docking experiment result, as the compounds did not interact
favorably with the DNA sequence and failed to stabilize it
compared to a control DNA minor groove binder.
Mode of Killing of EMRSA-15 and VRE-12201 by
Compounds 8, 13, and 14. The mode of killing of the three
most active compounds (8, 13, and 14) was determined at a
supra-inhibitory concentration (4 × MIC) against VRE-12201
and EMRSA-15; the results are reported in Figure 4. All three
compounds showed rapid bactericidal activity against the two
strains tested, with the number of colonies below the limit of
detection of the assay by 2 h after exposure to compounds 13
and 14 and 4 h with compound 8. A small population of cells
was detected after 24 h of treatment of strain VRE 12201 with
compound 8. This population was subsequently tested for
increased resistance to compound 8; no change in MIC level
was observed, indicating that this population is not comprised
of true resistant mutants but rather is potentially a “persister
population” of cells with reduced metabolic activity. No
bacterial survival was detected for compound 13 in either
species or for compound 8 in EMRSA-15. Interestingly, a small
population of bacterial recovery was observed in both species
for compound 14 after 10 h.
Evaluation of Microbiological Activity against the
Gram-Negative Panel. The most active compounds (8, 10,
13, and 14) were also evaluated against Gram-negative bacteria.
Two strains each (one drug-sensitive and one multidrug
resistant) from Acinetobacter baumannii, Pseudomonas aerugino-
sa, and Klebsiella pneumoniae were tested in the presence or
absence of the eﬄux pump inhibitor phenylalanine-arginine β-
naphthylamide (PaβN) in the presence of Mg2+ ions (Table 5).
All strains tested showed no susceptibility to compounds 8 and
10 (MIC values of >32 μg/mL). Some activity was shown for
compound 13 against A. baumannii (MIC 16 μg/mL) and the
drug sensitive K. pneumoniae strain M6 (MIC 32 μg/mL), but
no activity was observed against P. aeruginosa. To assess the
eﬀect of the Gram-negative membrane permeability barrier on
the activity of the compounds, the selective membrane
permeabilizer, polymixin B nonapeptide (PMBN) was used.
Little eﬀect was observed with either compound 8 or 10, with
only strain M6 showing any signiﬁcant reduction in MIC. In
the case of compounds 13 and 14, MICs were signiﬁcantly
reduced by addition of PMBN by at least 4-fold for the two K.
pneumoniae isolates and by greater than 16-fold for the two P.
aeruginosa isolates, with a 2-fold reduction also seen in A.
baumannii (ﬁnal MICs being 8−16, 4, and 8 μg/mL,
respectively). The addition of PAβN in the presence of Mg2+
to stabilize the membrane reduced the MIC value for all strains,
except PA01 by 2−4-fold. As only one strain (K. pneumoniae
M6) showed a ≥4-fold reduction in MIC, the data does not
conclusively show that RND-family eﬄux pumps play a role in
eﬄux of the compounds from the cell; further studies would be
needed to understand the role of RND pumps and their
speciﬁcity for these compounds. The poor activity of
compounds 13 and 14 and more generally of the series against
Gram-negative strains could be explained by the intrinsic
chemical−physical properties of this class of molecules. Triaryl
benzimidazole molecules have relatively high lipophilicity,
which is not usually associated with molecules that are active
against Gram-negative bacteria as they typically ﬁt in a more
hydrophilic chemical space. In addition the membrane structure
of Gram-negative bacteria (having an inner and outer
membrane) means that activity of compounds is often
decreased relative to Gram-positive bacteria due to poor
penetration of the compound through the cell membrane. The
Table 4. DNA Duplex Stabilization for Compound 8, 13, 14,
and Netropsina
ligand ΔTm
8 (1 μM) 0.2
8 (5 μM) 0.9
13 (1 μM) 0.4
13 (5 μM) 2.1
14 (1 μM) 0.3
14 (5 μM) 0.6
Netropsin (1 μM) 16.5
Netropsin (5 μM) 22.2
aΔTm values are reported in the table in °C in comparison to the
control. Assay conducted in triplicate.
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potentiation observed with PMBN in the K. pneumoniae and P.
aeruginosa strains reﬂects the poor relative permeability of these
membranes compared to A. baumannii isolates where only
limited potentiation is observed. This is in agreement with
observations suggesting that the membrane of P. aeruginosa, in
particular, is less permeable than other Gram-negative bacteria.
Preliminary Mechanistic Evaluation. DNA-interactive
molecules are known to inhibit DNA-processing enzymes,32,33
and bis-benzimidazoles have been shown to inhibit gyrases in S.
aureus.34 Therefore, we investigated the possibility that these
compounds might also exert their antimicrobial activity by
interacting with DNA processing enzymes. A molecular
docking experiment with the bacterial gyrase from Staph-
ylococcus aureus (PDB 2XCT) showed compound 13 favorably
interacted with the binding pocket of both the subunits of the
enzyme, and the best pose gave a CHEM Score of 28.65 and
aﬃnity of −34.27 (kcal/mol) for subunit 1 of gyrase A and a
CHEM Score of 26.52 and aﬃnity of −32.50 (kcal/mol) for
subunit 2 of gyrase A (Figure 5 and Supporting Information,
Table S3). The 2D models shown in Figure 5C suggests
compound 13 forms three conventional hydrogen bonds with
lysine 43, arginine 92, and phenylalanine 97 of the subunit 1 of
DNA gyrase A. Similarly, compound 13 also forms three
conventional hydrogen bonds with serine 85, arginine 92, and
serine 98 of the subunit 2 of gyrase A. A number of
hydrophobic interactions with diﬀerent amino acids of subunit
1 of gyrase A and electrostatic interactions with the subunit 2 of
gyrase A enzyme were also observed. The molecular modeling
study suggested that the newly designed scaﬀold inhibits DNA
gyrase by directly interacting with the enzyme. The in silico
observation was validated by carrying out a DNA gyrase
inhibition assay using a commercial S. aureus gyrase super-
coiling high throughput plate assay (no. SATRG01) kit
obtained from Inspiralis (Norwich, UK), and the result is
shown in Figure 6. At concentrations around the MIC for S.
aureus (0.5 μg/mL), compound 13 showed 65.2 ± 9.8%
inhibition of the gyrase and this was comparable to levoﬂoxacin,
a known DNA gyrase inhibitor, which showed inhibition of
57.9 ± 3.5% at the same concentration. Although only assessed
over a small concentration range and under standard conditions
as deﬁned for the gyrase assay kit, these results suggest that
compound 13 is an eﬃcient inhibitor of S. aureus gyrase and
this is likely to be the principle mechanism by which this
compound kills the bacterial cells. Interestingly, compound 13
showed rapid bactericidal activity in time kill studies with both
EMRSA-15 and VRE12201. When levoﬂoxacin was used, also
at 4 × MIC, against the same strains it achieved less than a 3-
log bacterial kill with VRE12201 at 24 h (and would be deﬁned
as being bacteriostatic on this basis) and showed a 3-log kill
against EMRSA15 at 6 h with a further log-reduction to below
the limits of detection of viable bacteria (>6-log reduction) only
at 24 h (Figure 4). This suggests that the mechanism of
inhibition of S. aureus gyrase by compound 13 is probably
Figure 4. Response of EMRSA-15 and VRE-12201 strains to treatment with suprainhibitory concentrations (4 ×MIC) of compounds 8, 13, and 14.
Table 5. Antibacterial Activity of Compounds 8, 10, 13, and 14 against Gram-Negative Bacteria in the Presence and Absence of
Eﬄux Pump Inhibitor PaβN and Membrane Permeabilizer PMBN
Gram-negative strains MIC (μg/mL)
A. baumannii K. pneumoniae P. aeruginosa
compd AYE ATCC 17978 M6 NCTC 13368 PA01 NCTC 13437
8 >32 >32 >32 >32 >32 >32
8+PaβN+Mg2+ >32 32 >32 >32 >32 >32
8+PMBN 32 32 16 >32 >32 >32
10 >32 >32 >32 >32 >32 >32
10+PaβN+Mg2+ >32 >32 >32 >32 >32 >32
10+PMBN >32 >32 >32 >32 >32 >32
13 16 16 32 >32 >32 >32
13+PaβN+Mg2+ 8 8 8 32 >32 16−32
13+PMBN 8 8 8 16 4 4
14 >32 >32 >32 >32 >32 >32
14+PaβN+Mg2+ 16 8 16 32 >32 >32
14+PMBN 8 8 16 32 16 16
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diﬀerent from levoﬂoxacin and that this results in a much more
potent bactericidal kill in the two Gram-positive strains tested.
■ CONCLUSION
A new triaryl benzimidazole scaﬀold with a lower predicted
aﬃnity for DNA binding has been designed, synthesized, and
evaluated for its antibacterial activity. The compounds showed
a negligible DNA binding at high concentrations and were
found to be nontoxic against eukaryotic cell lines. The most
active compounds 8, 13, and 14 showed rapid bactericidal
activity against multidrug-resistant Gram-positive MRSA and
VRE bacteria, and, for the ﬁrst time in the case of this class of
compound, activity against speciﬁc strains of Gram-negative
bacteria. The chemical scaﬀold appears to have a very restricted
SAR, with limited modiﬁcations allowed in order to retain
activity. The lack of DNA stabilization suggests that the
antibacterial activity of these compounds is not related to their
DNA binding ability. The compounds appeared to work by
inhibiting DNA gyrase, and the most active compound showed
notable inhibition of the gyrase enzyme from S. aureus.
Compounds with antibacterial activity are in urgent need to
combat the growing antimicrobial resistance problem, and this
new scaﬀold provides an opportunity to develop a more potent
antibacterial agent by carrying out further medicinal chemistry
modiﬁcations. Further studies on the mechanism of gyrase
inhibition, to understand the fundamental diﬀerences with
ﬂuoroquinolones, are also merited.
■ EXPERIMENTAL SECTION
Synthesis: General Material and Methods. All solvents and
reagents for the synthesis were obtained from commercially available
sources including, among others, Sigma-Aldrich, Fisher Scientiﬁc,
Fluorochem, and Alfa Aesar. Thin-layer-chromatography (TLC)
analysis was performed on silica gel plates (E. Merck silica gel 60
F254 plates) and visualized by ultraviolet (UV) radiation at 254 nm.
Flash chromatography for the puriﬁcation of the compound was
performed with silica gel as a stationary phase (Merck 60, 230−400
mesh). 1H and 13C nuclear magnetic resonance (NMR) analyses were
performed on a Bruker Spectrospin 400 MHz spectrometer. LC-MS
analyses were performed on a Waters Alliance 2695 system, eluting in
gradient. The analyses were performed on a Monolithic C18 50 mm ×
Figure 5. (A) Molecular model showing the interaction of compound 13 with the subunit-1 of the S. aureus gyrase A. (B) Molecular model showing
the interaction of compound 13 with the subunit-2 of the S. aureus gyrase A. (C) 2D model showing the key interactions between compound 13
with the binding site in the subunit-1 of the S. aureus gyrase A. (D) 2D model showing the key interactions between compound 13 with the binding
site in the subunit-2 of the S. aureus gyrase A.
Figure 6. Percentage of inhibition of S. aureus gyrases by compound
13, levoﬂoxacin has been used as a control. The data is an average of
three independent experiments.
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4.60 mm column by Phenomenex. UV detection was performed on a
diode array detector. Mass spectra were registered in both ESI+ and
ESI− modes. Melting points were determined using a Stuart SMP30
melting point apparatus.
All the compounds tested for their biological activity are >95% pure,
conﬁrmed with two diﬀerent HPLC analysis methods (S6). The
HRMS analyses were performed on a Thermo Scientiﬁc Exactive
HCD Orbitrap mass spectrometer. The hydrogenation reaction was
conducted using a Parr hydrogenation system. Synthetic intermediates
and the ﬁnal compound bearing tertiary aminic tail were puriﬁed by
the “catch and release” method using a SCX-cartridge by Biotage.
Initially, the cartridge was activated with DCM and MeOH. After the
activation, the reaction mixture was loaded on the cartridge and
periodically washed with DCM, DMF, and MeOH (2 column volume
each). At this point, the pure sample was recovered, washing the
cartridge with NH3 6 M solution in MeOH.
Synthesis of Triaryl Benzimidazole Series Analogues. Syn-
thesis of 4-(5-Bromo-pyridin-2-ylamino)-3-nitro-benzoic Acid Meth-
yl Ester (3). NaH 60% dispersion in mineral oil (1.340 g, 1.5 equiv)
was added to a solution of 5-bromo-pyridin-2-ylamine (4.275 g, 1
equiv) in THF (60 mL), with the suspension kept under a magnetic
stirrer at 0 °C. After 20 min, 4-ﬂuoro-3-nitro-benzoic acid methyl ester
(5.0 g, 1 equiv) was added to the suspension that was left under a
magnetic stirrer, at 25 °C, for 15 h and monitored by TLC until
completion. After 15 h, EtOH (40 mL) and H2O (150 mL) were
added to the reaction mixture and a yellow solid precipitated. The
suspension was ﬁltered under a vacuum giving pure 3 (5.9 g, 68%), as
a dark-yellow solid, mp 172.2−172.8 °C. 1H NMR (400 MHz,
chloroform-d) δ: 10.52 (1 H, s), 8.94 (1 H, d, J = 2.01 Hz), 8.86 (1 H,
d, J = 9.06 Hz), 8.44 (1 H, d, J = 2.52 Hz), 8.19 (1 H, dd, J = 9.19, 2.14
Hz), 7.79 (1 H, dd, J = 8.56, 2.52 Hz), 6.93 (1 H, d, J = 8.81 Hz), 3.95
(3 H, s). 13C NMR (101 MHz, chloroform-d) δ: 164.8, 151.1, 148.4,
141.2, 140.5, 135.8, 133.5, 128.1, 121.3, 118.7, 115.4, 113.6, 52.1. m/z
(+EI) calcd for C13H10BrN3O4 (M)
+ 350.9, found 351.8 ([M] + H)+.
Synthesis of 3-Amino-4-(5-bromo-pyridin-2-ylamino)-benzoic
Acid Methyl Ester (4). A solution was prepared by dissolving 3 (5.9
g, 1 equiv) in a mixture of MeOH and DCM (60 mL, 50/50, v/v). A
catalytic amount of Raney nickel slurry in H2O (400 mg) was added to
the solution, and the resulting solution was transferred to a vial and
hydrogenated at 40 psi for 1 h in a Parr hydrogenation system until
TLC showed completion of the reaction. Subsequently, the reaction
mixture was ﬁltered on a Celite path, washing with DCM. The organic
phase was then evaporated using a rotary evaporator to give pure 4
(5.2 g, > 95%) as a light-brown solid, mp 194.5−195.8 °C. 1H NMR
(400 MHz, DMSO-d6) δ: 8.31 (1 H, s), 8.19 (1 H, d, J = 2.52 Hz),
7.73 (1 H, dd, J = 8.94, 2.64 Hz), 7.67 (1 H, d, J = 8.31 Hz), 7.39 (1 H,
d, J = 2.01 Hz), 7.19 (1 H, dd, J = 8.31, 2.01 Hz), 6.81 (1 H, d, J = 9.06
Hz), 5.17 (2 H, s), 3.79 (3 H, s). 13C NMR (101 MHz, DMSO-d6)
δ:166.4, 154.8, 147.6, 140.1, 139.7, 130.6, 124.1, 117.8, 115.9, 112.4,
108.2, 54.9, 51.6. m/z (+EI) calcd for C13H12BrN3O2 (M)
+ 321.0,
found 321.9 ([M] + H)+.
Synthesis of 1-(5-Bromo-pyridin-2-yl)-2-methyl-1H-benzoimida-
zole-5-carboxylic Acid Methyl Ester (5). A solution was prepared by
dissolving 4 (5 g, 1 equiv) in THF (130 mL). Trimethyl orthoacetate
(4.07 mL, 2 equiv) and p-TsOH (1.377 g, 0.5 equiv) were sequentially
added to this solution, and the reaction mixture was left at reﬂux for 15
h until TLC showed completion of the reaction. The reaction mixture
was then evaporated in vacuum, with the residue dissolved in AcOEt
(50 mL) and sequentially washed with a saturated solution of
NaHCO3 (60 mL) and brine (60 mL). The organic phase was dried
over anhydrous MgSO4 and evaporated using a rotary evaporator. The
obtained crude was puriﬁed by ﬂash column chromatography (mobile
phase: DCM/AcOEt, 80/20, v/v), obtaining pure 5 (3.7 g, 69%) as a
white solid, mp 141.5−141.9 °C. 1H NMR (400 MHz, chloroform-d)
δ: 8.77 (1 H, d, J = 2.52 Hz), 8.45 (1 H, d, J = 1.76 Hz), 8.11 (1 H, dd,
J = 8.31, 2.52 Hz), 8.00 (1 H, dd, J = 8.44, 1.64 Hz), 7.41 (1 H, d, J =
8.31 Hz), 7.38 (1 H, d, J = 8.56 Hz), 3.96 (3 H, s), 2.70 (3 H, s). 13C
NMR (101 MHz, chloroform-d) δ: 153.1, 151.2, 147.9, 142.5, 141.6,
137.9, 136.6, 125.3, 124.9, 121.6, 121.0, 120.0, 109.8, 52.2, 15.5. m/z
(+EI) calcd for C15H12BrN3O2 (M)
+ 345.0, found 345.8 ([M] + H)+.
Synthesis of 1-[5-(3-Amino-phenyl)-pyridin-2-yl]-2-methyl-1H-
benzoimidazole-5-carboxylic Acid Methyl Ester (6). A solution was
prepared by dissolving 5 (2.1 g, 1 equiv) in anhydrous THF (70 mL)
under an N2 atmosphere. The 3-aminophenylboronic acid mono-
hydrate (1.633 g, 2 equiv), K2CO3 (2.48 g, 3 equiv), and a catalytic
amount of tetrakis(triphenyl)palladium(0) (0.693 g, 0.1 equiv) were
sequentially added to this solution. The reaction mixture was kept at
reﬂux under a magnetic stirrer for 15 h until TLC showed completion
of the reaction. The reaction mixture was concentrated using a rotary
evaporator, and the crude was puriﬁed by ﬂash column chromatog-
raphy (mobile phase: from DCM/AcOEt, 80/20, v/v to DCM/
AcOEt, 60/40, v/v) to give 6 (1.74 g, 81%) as a brown solid, mp
194.5−195.6 °C. 1H NMR (400 MHz, DMSO-d6) δ: 8.91 (1 H, d, J =
2.27 Hz), 8.29 (1 H, dd, J = 8.31, 2.52 Hz), 8.25 (1 H, s), 7.90 (1 H,
dd, J = 8.56, 1.26 Hz), 7.84 (1 H, d, J = 8.06 Hz), 7.57 (1 H, d, J = 8.31
Hz), 7.20 (1 H, t, J = 7.81 Hz), 6.98 (1 H, t, J = 1.89 Hz), 6.95 (1 H, d,
J = 7.55 Hz), 6.68 (1 H, dd, J = 8.44, 1.64 Hz), 5.31 (2 H, s), 3.89 (3
H, s), 2.65 (3 H, s). 13C NMR (101 MHz, DMSO-d6) δ: 166.6, 153.4,
149.4, 147.3, 138.1, 137.2, 136.5, 129.8, 123.9, 120.4, 120.0, 114.4,
114.2, 112.1, 111.0, 52.0, 14.9. m/z (+EI) calcd for C21H18N4O2 (M)
+
358.1, found 359.0 ([M] + H)+.
Synthesis of 2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-
carbonyl)-amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-car-
boxylic Acid Methyl Ester (7). HBTU (0.212 g, 2 equiv) and DIPEA
(0.144 mL, 3 equiv) were sequentially added to a solution of the
appropriate benzofused carboxylic acid (2 equiv) in DMF (4 mL) and
kept under a magnetic stirrer for 20 min. At that point, 6 (0.1 g, 1
equiv) was added to the solution and the reaction mixture was left
under a magnetic stirrer at 50 °C for 2 days. The reaction did not go to
completion as evidenced by TLC and LC-MS analysis, and it was
decided to quench the reaction and to proceed with the workup. The
solvent was evaporated using a rotary evaporator adding toluene to the
reaction mixture to enhance the evaporation of DMF. The crude of
reaction was then puriﬁed by ﬂash column chromatography (mobile
phase: from DCM 100 to DCM/MeOH, 98/2, v/v), obtaining the
desired product 7 (0.08 g, 56%) as a brown solid, mp 265.0 °C. 1H
NMR (400 MHz, DMSO-d6) δ:10.35 (1 H, s), 8.30 (1 H, s), 8.25 (1
H, d, J = 1.26 Hz), 7.94 (2 H, d, J = 8.56 Hz), 7.81−7.91 (3 H, m),
7.73 (2 H, d, J = 8.31 Hz), 7.58 (1 H, s), 7.52 (2 H, d, J = 4.78 Hz),
7.33 (1 H, d, J = 8.56 Hz), 3.89 (3 H, s), 2.67 (3 H, s), 2.55 (3 H, s).
13C NMR (101 MHz, DMSO-d6) δ:166.6, 166.2, 153.5, 147.7, 147.5,
142.0, 140.4, 138.1, 137.5, 136.3, 135.7, 129.6, 127.6, 124.0, 123.9,
122.0, 121.3, 121.3, 120.6, 120.3, 120.0, 118.8, 111.0, 52.1, 15.0, 14.8.
HRMS (EI, m/z): calcd for C30H24N6O3 ([M] + H)
+ 517.1983, found
517.1994.
General Procedure for the Synthesis of Tertiary Aminic Tail
Derivatives (8−14). The corresponding benzofused amide derivative 7
(1.3 equiv) was dissolved in MeOH (4 mL), and 0.5 M NaOH
aqueous solution (5.2 equiv) was added to the solution. The reaction
mixture was left under a magnetic stirrer for 15 h at 25 °C until TLC
showed complete formation of the acid as a sodium salt. The PH of
the solution was adjusted to 3 through the addition of an HCl 1 M
aqueous solution, causing the precipitation of a solid that was ﬁltered
under a vacuum, collected, and dissolved in DMF (3 mL). HBTU (2
equiv) and DIPEA (3 equiv) were sequentially added to the solution
that was kept under a magnetic stirrer for 20 min. At that point, the
corresponding tertiary aminic tail (1 equiv) was added to the solution
that was left under a magnetic stirrer. After 4 h, TLC showed
completion of the reaction. The puriﬁcation of the compounds was
performed using a SCX cartridge as described in the section “general
chemistry”, obtaining pure compounds 8−14. For some compounds, a
second puriﬁcation using ﬂash column chromatography (mobile
phase: from DCM/MeOH, 90/10, v/v to DCM/MeOH/NH3 in
MeOH, 90/10/0.1, v/v/v) was necessary to obtain the desired level of
purity.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
(2-Dimethylamino-ethyl)-amide (8). Yield 0.040 g (77%) as a brown
oil. 1H NMR (400 MHz, DMSO-d6) δ: 12.50 (1 H, s), 10.37 (1 H, s),
9.01 (1 H, s), 8.58 (1 H, t, J = 6.40 Hz), 8.40 (1 H, dd, J = 9.20, 3.60
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00108
J. Med. Chem. 2017, 60, 6045−6059
6054
Hz), 8.33 (1 H, s), 8.19 (1 H, d, J = 3.20 Hz), 7.92 (1H, d, J = 8.60
Hz), 7.89 (1 H, d, J = 6.00 Hz), 7.84 (1 H, d, J = 7.60 Hz), 7.80 (1 H,
d, J = 8.00 Hz), 7.53−7.59 (4 H, m), 3.5 (2 H, m), 2.66 (3 H, s), 2.5
(5 H, m), 2.32 (6 H, s). 13C NMR (101 MHz, DMSO-d6) δ:166.3,
166.2, 160.5, 159.1, 152.7, 150.3, 149.0, 147.9, 147.5, 145.2, 141.9,
140.4, 137.5, 136.6, 135.5, 133.6, 129.6, 129.0, 127.7, 122.3, 122.0,
121.3, 120.4, 118.8, 115.8, 110.4, 58.5, 45.0, 37.2, 15.0, 14.8. HRMS
(EI, m/z): calcd for C33H32N8O2 ([M] + H)
+ 573.2721, found
573.2716.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
(3-Pyrrolidin-1-yl-propyl)-amide (9). Yield 0.022 g (79%) as a brown
oil. 1H NMR (400 MHz, DMSO-d6) δ: 12.51 (1 H, s), 10.37 (1 H, s),
9.01 (1 H, s), 8.61 (1 H, t, J = 4.80 Hz), 8.40 (1 H, dd, J = 9.20, 3.60
Hz), 8.32 (1 H, s), 8.17 (1 H, s), 7.93 (1 H, d, J = 5.60 Hz), 7.89 (1 H,
d, J = 7.60 Hz), 7.84 (1 H, d, J = 6.00 Hz), 7.78 (1 H, d, J = 8.00 Hz),
7.53−7.59 (4 H, m), 3.35 (2H, m), 2.67 (3 H, s), 2.5 (9 H, m), 1.69−
1.78 (6 H, m). 13C NMR (101 MHz, MeOH-d4) δ:170.3, 169.4, 163.9,
161.5, 155.7, 155.2, 149.2, 149.1, 142.8, 141.2, 139.1, 138.3, 138.3,
130.9, 130.0, 129.9, 129.2, 126.3, 124.1, 123.9, 123.0, 122.4, 121.8,
120.8, 118.8, 111.8, 55.1, 55.0, 39.4, 29.2, 24.2, 15.0, 14.5. HRMS (EI,
m/z): calcd for C36H36N8O2 ([M] + H)
+ 613.3034, found 613.3031.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
[3-(4-Methyl-piperazin-1-yl)-propyl]-amide (10). Yield 0.025 g (86%)
as a brown oil. 1H NMR (400 MHz, DMSO-d6) δ: 12.51 (1 H, s),
10.35 (1 H, s), 9.0 (1 H, s), 8.54 (1 H, t, J = 4.80 Hz), 8.40 (1 H, dd, J
= 9.20, 3.60 Hz), 8.32 (1 H, s), 8.19 (1 H, s), 7.93 (1 H, d, J = 6.40
Hz), 7.89 (1 H, d, J = 6.00 Hz), 7.84 (1 H, d, J = 6.20 Hz), 7.79 (1 H,
d, J = 8.4 Hz), 7.56−7.59 (4 H, m), 3.35 (2H, m, 2.67 (3 H, s), 2.5 (5
H, m), 2.36−2.42 (8 H, m), 2.21 (3 H, s), 1.71−1.77 (2 H, m). 13C
NMR (101 MHz, DMSO-d6) δ: 173.1, 166.2, 166.1, 154.2, 153.4,
152.7, 147.4, 146.8, 146.5, 141.9, 139.1, 137.4, 136.5, 136.3,135.7,
135.4, 129.5, 129.2, 122.2, 120.4, 118.9, 117.6, 111.4, 55.5, 54.3, 52.2,
48.5, 45.2, 40.4, 33.7, 26.1, 15.0, 14.7. HRMS (EI, m/z): calcd for
C37H39N9O2 ([M] + H)
+ 642.3299, found 642.3302.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
(3-Diethylamino-propyl)-amide (11). Yield 0.027 g (67%) as a brown
oil. 1H NMR (400 MHz, DMSO-d6) δ: 12.54 (1 H, s), 10.37 (1 H, s),
9.01 (1 H, s), 8.68 (1 H, t, J = 4.80 Hz), 8.40 (1 H, dd, J = 9.20, 3.60
Hz), 8.33 (1 H,s), 8.21 (1 H, s), 7.85−7.93 (2 H, m), 7.80−7.82 (2 H,
m), 7.52−7.58 (4H, m), 3.35 (2H, m), 3.01 (4 H, m), 2.67 (3 H, s),
2.5 (5 H, m), 1.88−1.91 (2 H, m), 1.15 (6 H, t, J = 5.60 Hz). 13C
NMR (101 MHz, DMSO-d6) δ: 166.6, 166.2, 164.0, 159.0,158.4,
156.0, 152.8, 147.8, 147.4, 146.4, 141.9, 140.3, 137.4, 136.7, 136.2,
135.5, 129.5, 128.8,122.3, 121.9, 120.4, 120.3, 118.8, 117.7, 112.2,
110.4, 48.8, 46.0, 35.8, 29.0, 15.0, 14.7, 8.9. HRMS (EI, m/z): calcd for
C36H38N8O2 ([M] + H)
+ 615.3190, found 615.3189.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
(3-Morpholin-4-yl-propyl)-amide (12). Yield 0.025 g (60%) as a
brown oil. 1H NMR (400 MHz, DMSO-d6) δ: 12. 56 (1 H, s), 10.36
(1 H, s), 9.01 (1 H, s), 8.52 (1 H, t, J = 4.80), 8.40 (1 H, dd, J = 9.20,
3.60 Hz), 8.32 (1 H, s), 8.19 (1 H, s), 7.93 (1 H, d, J = 8.00 Hz), 7.89
(1 H, d, J = 8.00 Hz), 7.84 (1 H, d, J = 7.20 Hz), 7.78 (1 H, d, J = 8.00
Hz), 7.55−7.59 (4 H, m), 3.54−3.59 (4 H, m), 3.5 (2 H, m), 2.67 (3
H, s), 2.5 (5 H, m), 2.31−2.37 (4 H, br s), 1.69−1.76 (2 H, m). 13C
NMR (101 MHz, DMSO-d6) δ: 166.2, 166.1, 152.6, 147.9, 147.4,
145.9, 143.1, 141.9, 141.2, 140.3, 137.4, 136.5, 136.3, 135.4, 129.5,
129.2, 122.2, 122.0, 121.6, 120.4, 120.2, 118.8, 117.6, 110.7, 110.3,
66.1, 56.1,53.3, 49.4, 48.5, 25.9, 15.0, 14.7. HRMS (EI, m/z): calcd for
C36H36N8O3 ([M] + H)
+ 629.2983, found 629.2988.
2-Methyl-1-(5-{3-[(2-methyl-3H-benzoimidazole-5-carbonyl)-
amino]-phenyl}-pyridin-2-yl)-1H-benzoimidazole-5-carboxylic Acid
(3-Dimethylamino-propyl)-amide (13). Yield 0.025 g (94%) as a
brown oil. 1H NMR (400 MHz, DMSO-d6) δ: 12.51 (1 H, s), 10.37 (1
H, s), 9.02 (1 H, s), 8.58 (1 H, t, J = 4.80 Hz), 8.40 (1 H, dd, J = 9.20,
3.60 Hz), 8.33 (1 H, s), 8.18 (1 H, d, J = 3.20 Hz), 7.92 (1H, d, J =
8.60 Hz), 7.89 (1 H, d, J = 6.00 Hz), 7.84 (1 H, d, J = 7.60 Hz), 7.81
(1 H, d, J = 8.00 Hz), 7.53−7.59 (4 H, m), 3.50 (2 H, m), 2.67 (3 H,
s), 2.5 (5 H, m), 2.32 (6 H, s), 1.72−1.78 (2 H, m). 13C NMR (101
MHz, DMSO-d6) δ: 166.4, 166.2 153.1, 152.7, 147.9, 147.5, 142.2,
142.0, 140.4, 140.3, 137.5, 136.6, 136.3, 135.5, 133.7, 130.3, 129.5,
129.1 125.5, 125.1, 122.3, 122.0, 120.4, 120.3, 118.8, 117.6, 113.7,
110.4, 56.4, 44.3, 37.5, 26.4,15.0, 14.7. HRMS (EI, m/z): calcd for
C34H34N8O2 ([M] + H)
+ 587.2877, found 587.2879.
N-(4-(Dimethylamino)butyl)-2-methyl-1-(5-(3-(2-methyl-1H-
benzo[d]imidazole-6-carboxamido)phenyl)pyridin-2-yl)-1H-benzo-
[d]imidazole-5-carboxamide (14). Yield 0.035 g (71%) as a brown
oil. 1H NMR (400 MHz, DMSO-d6) δ: 10.40 (1 H, s), 9.01 (t, J = 2.04
Hz, 1 H), 8.39 (1 H, dt, J = 8.32 Hz), 8.32 (1 H, s), 8.19−8.23 (2 H,
m), 7.91−7.94 (1 H, m), 7.87−7.90 (1 H, m), 8.82−7.84 (2 H, m),
7.52−7.58 (4 H, m), 3.23−3.26 (2 H, m), 3.06−3.07 (6 H, m), 2.65 (3
H, s), 2.54 (3 H, s), 1.82−1.85 (2 H, m), 1.51−1.63 (4 H, m). 13C
NMR (101 MHz, DMSO-d6) δ: 166.2, 163.8, 152.6, 147.8, 147.4,
141.9, 140.4, 137.4, 136.5, 136.2, 135.6, 135.4, 129.5, 129.3, 129.1,
127.7, 127.5, 124.6, 122.3, 121.8, 120.4, 120.2, 119.2, 118.8, 117.7,
110.3, 69.7, 45.1, 41.9, 31.8, 30.3, 15.0, 14.7. HRMS (EI, m/z): calcd
for C35H36N8O2 ([M] + H)
+ 601.3034, found 601.3033.
Synthesis of Double Aminic Tails Derivative 17. Synthesis of
Methyl 2-(3-(Dimethylamino)propyl)-1H-benzo[d]imidazole-6-car-
boxylate (15). Methyl 3,4-diaminobenzoate (0.050 g, 1 equiv) and
4-(dimethylamino)butanoic acid hydrochloride (1 equiv) were put
into a MW vial in the presence of DIPEA (2 equiv) and
propylphosphonic anhydride (T3P) 50% solution in ethyl acetate (1
equiv). The reaction mixture was heated at 160 °C for 40 min. The
obtained crude of the reaction was dissolved in ethyl acetate (10 mL)
and subsequently extracted with NaHCO3 saturated aqueous solution
(2 × 15 mL). The collected organic phase was dried over anhydrous
MgSO4 and evaporated using a rotary evaporator. The obtained crude
was puriﬁed by ﬂash column chromatography (mobile phase: initially
DCM/MeOH, 80/20, v/v then DCM/NH3 solution in MeOH, 95/5,
v/v), obtaining pure 15 (0.054 g, 69%) as a transparent oil. 1H NMR
(400 MHz, chloroform-d) δ: 8.24 (s, 1H), 7.84−7.99 (m, 1H), 7.55
(d, J = 8.56 Hz, 1H), 3.94 (s, 3H), 3.08−3.20 (m, 2H), 2.51−2.63 (m,
2H), 2.40 (s, 6H), 1.95−2.02 (m, 2H). 13C NMR (101 MHz,
chloroform-d) δ: 167.9, 158.2, 143.1, 138.3, 123.6, 123.4, 116.6, 114.5,
59.6, 52.0, 45.0, 28.8, 24.4. m/z (+EI) calcd for C14H19N3O2 (M)
+
261.1, found 262.0 ([M] + H)+
Synthesis of Methyl 1-(5-(3-(2-(3-(Dimethylamino)propyl)-1H-
benzo[d]imidazole-6-carboxamido)phenyl)pyridin-2-yl)-2-methyl-
1H-benzo[d]imidazole-5-carboxylate (16). Compound 15 (0.126 g, 2
equiv) was dissolved in MeOH (12 mL) and added to 0.5 M NaOH
aqueous solution (6 equiv). The solution was left under a magnetic
stirrer for 15 h until TLC showed total hydrolysis of the ester moiety.
The pH of the solution was adjusted to 3 through the addition of HCl
1 M aqueous solution, with the solvent then evaporated under reduced
pressure. The obtained white solid was dissolved in DMF (4 mL), and
the same procedure used for the synthesis of benzofused amide
derivative of 6 was applied. The puriﬁcation of the crude of reaction
was performed using a SCX cartridge as described in the section
“general chemistry”. After that, a puriﬁcation by column chromatog-
raphy (mobile phase: from DCM/MeOH, 90/10, v/v to DCM/
MeOH/NH3 in MeOH, 90/10/0.1, v/v/v)) was required to obtain
pure 16 (0.050 g, 35%) as a brown oil. 1H NMR (400 MHz,
chloroform-d) δ: 8.94 (d, J = 3.02 Hz, 1H), 8.50 (s, 1H), 8.46 (d, J =
1.26 Hz, 1H), 8.28 (t, J = 1.89 Hz, 1H), 8.20 (dd, J = 2.52, 8.31 Hz,
1H), 8.17 (s, 1H), 8.00 (dd, J = 1.51, 8.56 Hz, 1H), 7.77 (dd, J = 1.64,
8.44 Hz, 1H), 7.67 (d, J = 7.30 Hz, 1H), 7.58 (d, J = 8.31 Hz, 1H),
7.50−7.56 (m, 2H), 7.41−7.47 (m, 2H), 3.96 (s, 3H), 3.11−3.17 (m,
2H), 2.74 (s, 3H), 2.60−2.66 (m, 2H), 2.45 (s, 6H), 2.01−2.05 (m,
2H). 13C NMR (101 MHz, chloroform-d) δ:167.6, 166.7, 153.4, 148.4,
148.2, 142.4, 139.5, 139.4, 138.1, 137.6, 137.4, 137.3, 136.9, 136.4,
133.1, 129.9, 128.1, 125.6, 125.0, 124.7, 121.9, 122.8, 120.9, 120.3,
119.8, 110.0, 59.7, 52.1, 44.7,, 28.7, 23.6, 15.4. m/z (+EI) calcd for
C34H33N7O3 (M)
+ 587.2, found 588.2 ([M] + H)+.
Synthesis of N-(3-(Dimethylamino)propyl)-1-(5-(3-(2-(3-
(dimethylamino)propyl)-1H-benzo[d]imidazole-6-carboxamido)-
phenyl)pyridin-2-yl)-2-methyl-1H-benzo[d]imidazole-5-carboxa-
mide (17). Compound 16 (0.020 g, 1.3 equiv) was dissolved in MeOH
(5 mL) and added to NaOH 0.5 M aqueous solution (5.2 equiv). The
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solution was left under a magnetic stirrer for 15 h until TLC showed
total hydrolysis of the ester moiety. The pH of the solution was
adjusted to 3 through the addition of HCl 1 M aqueous solution, with
the solvent then evaporated under reduced pressure. The obtained
white solid was dissolved in DMF (4 mL), and the same procedure
used for the synthesis of tertiary aminic tail derivatives was employed.
Puriﬁcation was performed using a SCX cartridge as described in the
section “general chemistry”. After that, a puriﬁcation by column
chromatography (mobile phase: from DCM/MeOH, 90/10, v/v to
DCM/MeOH/NH3 in MeOH, 90/10/1, v/v/v)) was required to
obtain pure 17 (0.014 g, 82%) as a brown oil. 1H NMR (400 MHz,
MeOH-d4) δ: 9.02 (d, J = 2.52 Hz, 1H), 8.44 (dd, J = 2.52, 8.31 Hz,
1H), 8.24−8.26 (m, 2H), 8.19 (d, J = 1.51 Hz, 1H), 7.92 (dd, J = 1.76,
8.56 Hz, 1H), 7.84 (d, J = 1.76 Hz, 1H), 7.79−7.83 (m, 2H), 7.65 (d, J
= 8.56 Hz, 1H), 7.54−7.60 (m, 3H), 3.51 (t, J = 6.80 Hz, 2H), 3.26 (d,
J = 7.05 Hz, 2H), 2.90−2.96 (m, 2H), 2.79−2.85 (m, 2H), 2.72 (s,
3H), 2.69 (s, 6H), 2.59 (s, 6H), 2.13−2.22 (m, 2H), 1.95−2.02 (m,
2H). 13C NMR (101 MHz, MeOH-d4) δ: 170.7, 169.4, 163.1, 158.4,
155.3, 149.3, 149.1, 142.8, 141.2, 139.2, 138.5, 138.4, 138.3, 130.9,
130.6, 130.3, 124.2, 124.0, 123.2, 122.5, 122.0, 120.9, 118.8, 111.9,
59.3, 57.8,, 45.2, 44.5,, 38.3, 27.8, 27.4, 25.5, 14.98. HRMS (EI, m/z):
calcd for C38H43N9O2 ([M] + H)
+ 658.3612, found 658.3611.
Synthesis of Compounds 18−19. Synthesis of 1-(5-Bromo-
pyridin-2-yl)-2-methyl-1H-benzoimidazole-5-carboxylic Acid (3-Di-
methylamino-propyl)-amide (18). Starting from compound 5 (0.035
g), the same procedure used for the synthesis of tertiary aminic tail
derivatives was applied. The puriﬁcation of the crude was obtained
using a SC-X cartridge according to the “catch and release” method
described in the general section, aﬀording pure 18 (0.030 g, 71%) as a
yellow oil. 1H NMR (400 MHz, MeOH-d4) δ: 8.82 (1 H, s), 8.32 (1
H, dd, J = 2.80, 8.00 Hz), 8.14 (1 H, s), 7.80 (1 H, d, d, J = 8.00 Hz),
7.66 (1H, d, J = 6.40 Hz), 7.51 (1 H, d, J = 7.2 Hz), 3.46 (2 H, t, J =
5.60 Hz), 2.67 (3 H, s), 2.47 (2 H, t, d, J = 6.40 Hz), 2.30 (6 H, s),
1.82−1.89 (2 H, m). 13C NMR (101 MHz, MeOH-d4) δ: 170.1, 155.1,
152.2, 148.9, 143.6, 142.7,138.0, 131.1, 124.0, 123.2, 121.6, 118.8,
111.8, 58.7, 45.4, 39.5, 37.0, 28.2, 15.0. HRMS (EI, m/z): calcd for
C19H22BrN5O ([M] + H)
+ 416.1080, found 416.1087.
Synthesis of 1-[5-(3-Amino-phenyl)-pyridin-2-yl]-2-methyl-1H-
benzoimidazole-5-carboxylic Acid (3-Dimethylamino-propyl)-
amide (19). Starting from compound 6 (0.1 g), the same procedure
used for the synthesis of compound 15 was applied, aﬀording pure 19
(0.095 g, 79%) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ: 8.89
(1 H, s), 8.67 (1 H, t, J = 5.20 Hz), 8.28 (1 H, dd, J = 2.80, 8.00 Hz),
8.20 (1 H, s), 7.81 (2 H, m), 7.51 (1 H, d, J = 8.00 Hz), 7.19 (1 H, t, J
= 8.00 Hz), 6.97 (2 H, m), 6.78 (1 H, dd, J = 2.80, 8.00 Hz),5.31 (2 H,
br s), 3.5 (2 H, m), 2.70 (2 H, t, J = 2.80 Hz), 2.67 (3 H, s), 2.45 (6 H,
s), 1.79−1.87 (2 H, m). 13C NMR (100 MHz, DMSO-d6) δ: 166.3,
152.6, 149.4, 147.5,147.2, 141.9, 137.1, 136.6, 136.5, 136.2, 129.8,
129.0, 122.3, 120.3, 117.7, 114.4, 114.1, 112.0, 110.3, 55.7, 48.5, 43.5,
25.6, 14.9, HRMS (EI, m/z): calcd for C25H28N6O ([M] + H)
+
429.2397, found 429.2405.
Synthesis of Compound 21. Synthesis of Methyl 1-(5-(3-
Benzamidophenyl)pyridin-2-yl)-2-methyl-1H-benzo[d]imidazole-5-
carboxylate (20). Starting from compound 6 (0.150 g), the same
procedure used for the synthesis of compound 7 was applied using
benzoic acid as carboxylic acid, aﬀording pure 20 (0.149 g, 77%) as a
white solid, mp 187.0 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.6 (1
H, br s), 10.43 (1 H, s), 9.01 (1 H, d, J = 2.04 Hz), 8.40 (1 H, dd, J =
8.28, 2.32 Hz), 8.25−8.30 (2 H, m), 7.97−8.02 (3 H, m), 7.89−7.92
(3 H, m), 7.71−7.73 (1 H, m), 7.52−7.62 (2 H, m), 7.39−7.43 (1 H,
m), 2.67 (3 H, s), 2.55 (3 H, s), 2.38 (2 H, t, J = 7.06 Hz), 2.23 (6 H,
s), 1.68−1.75 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ: 167.1,
166.2, 153.9, 148.2, 148.0, 142.5, 140.5, 138.6, 138.0, 136.8, 136.1,
135.3, 132.2, 130.1, 128.9, 128.2, 127.8, 124.9, 124.5, 124.4, 122.8,
121.1, 120.6, 119.4, 111.5, 110.8, 52.5, 15.4. m/z (+EI) calcd for
C28H22N4O3 (M)
+ 462.1, found 463.1 ([M] + H)+.
Synthesis of 1-(5-(3-Benzamidophenyl)pyridin-2-yl)-N-(3-
(dimethylamino)propyl)-2-methyl-1H-benzo[d]imidazole-5-carbox-
amide (21). Starting from compound 20 (0.050 g), the same
procedure used for the synthesis of tertiary aminic tail derivatives was
applied. The puriﬁcation of the crude was obtained using a SC-X
cartridge according to the “catch and release” method described in the
general section, aﬀording pure 21 (0.039 g, 79%) as a brown oil. 1H
NMR (400 MHz, DMSO-d6) δ: 10.46 (1H, s), 9.00−9.01 (m, 1H),
8.56−8.59 (1H, m), 8.40 (1H, dd, J = 8.36, 2.52 Hz), 8.30 (1H, t, J =
3.52 Hz), 8.18 (1H, d, J = 1.28 Hz), 8.00−8.02 (2H, m), 7.89−7.91
(2H, m), 7.78−7.81 (1H, m), 7.53−7.63 (6H, m), 3.29−3.32 (2H, m),
2.67 (3H, s), 2.28 (2H, t, J = 7.10 Hz) 2.14 (6H, s), 1.68 (2H, t, J =
14.2 Hz). 13C NMR (101 MHz, DMSO-d6) δ: 166.1, 165.7, 152.6,
147.9, 147.4, 141.9, 140.0, 137.4, 136.5, 136.3, 135.3, 134.7, 131.7,
129.6, 129.2, 128.4 (2C), 127.6 (2C), 122.3, 122.2, 120.4, 120.3, 118.8,
117.6, 110.3, 57.0, 46.7, 45.1, 37.8, 27.6, 15. HRMS (EI, m/z): calcd
for C32H32N6O2 ([M] + H)
+ 533.2660, found 533.2659.
Synthesis of Tetraryl Derivative 24. Synthesis of Methyl 1-(5-(3-
Bromophenyl)pyridin-2-yl)-2-methyl-1H-benzo[d]imidazole-5-car-
boxylate (22). Compound 6 (0.05 g) was dissolved in HBr 48%
aqueous solution (1.2 mL) and H2O (1.0 mL) and left under a
magnetic stirrer at 0 °C for 10 min. The reaction mixture was added to
a solution of NaNO2 (0.14 g) in H2O (0.6 mL) and left under a
magnetic stirrer for further 30 min at 0 °C. The now yellow-brown
solution was added dropwise to a solution of CuBr (0.37 g) in HBr
48% aqueous solution (1.6 mL) and kept under a magnetic stirrer at
50 °C. The temperature was maintained until no gas formation was
observed. The reaction mixture was added to ethyl acetate (10 mL)
and subsequently washed with NaHCO3 saturated aqueous solution (2
× 10 mL) and brine (2 × 10 mL). The organic phase was dried over
anhydrous MgSO4 and evaporated using a rotary evaporator. The
crude of the reaction was puriﬁed by column chromatography (mobile
phase: DCM/MeOH, 95/5, v/v), obtaining pure 22 (0.028 g, 48%) as
a white solid, mp 162.2−163.3 °C. 1H NMR (400 MHz, chloroform-
d) δ: 8.90 (d, J = 3.27 Hz, 1H), 8.47 (s, 1H), 8.15 (dd, J = 2.52, 8.31
Hz, 1H), 8.02 (dd, J = 1.51, 8.56 Hz, 1H), 7.83 (t, J = 1.89 Hz, 1H),
7.55−7.65 (m, 3H), 7.45 (m, 2H), 3.97 (s, 3H), 2.76 (s, 3H). 13C
NMR (101 MHz, chloroform-d) δ: 163.2, 148.3, 142.5, 138.5, 137.3,
135.2, 132.2, 131.8, 130.9, 130.3, 128.6, 128.5, 125.8, 124.8, 123.5,
121.6, 119.8,110.0, 52.2, 15.5. m/z (+EI) calcd for C21H16BrN3O2
(M)+ 421.0, found 422.0([M] + H)+.
Synthesis of Methyl 2-Methyl-1-(5-(3-(2-methyl-1H-benzo[d]-
imidazol-6-yl)phenyl)pyridin-2-yl)-1H-benzo[d]imidazole-5-carbox-
ylate (23). Compound 22 (0.031 mg, 1 equiv) was dissolved in
dioxane (2.5 mL) and H2O (0.5 mL) in a MW vial. 2-
Methylbenzimidazole-5-boronic pinacol ester (0.030 mg, 1.5 equiv),
tetrakis(triphenyl)palladium (0) (0.009 mg, 0.1 equiv), and K2CO3
(0.03 mg, 3 equiv) was sequentially added to the solution. The
reaction was heated using MW irradiation at 150 °C for 15 min,
causing complete reaction of the starting material. The reaction
mixture was evaporated under reduced pressure, and the crude of the
reaction was puriﬁed by column chromatography (mobile phase:
DCM/MeOH, 93/7, v/v), obtaining pure 23 (0.020 g, 58%) as a
white solid, mp 270.0 °C. 1H NMR (400 MHz, chloroform-d) δ: 8.98
(d, J = 1.76 Hz, 1H), 8.47 (d, J = 1.01 Hz, 1H), 8.23 (dd, J = 2.39, 8.18
Hz, 1H), 8.02 (dd, J = 1.51, 8.56 Hz, 1H), 7.90 (s, 1H), 7.84 (s, 1H),
7.74 (m, 1H), 7.62−7.66 (m, 2H), 7.51−7.61 (m, 3H), 7.47 (d, J =
8.56 Hz, 1H), 3.97 (s, 3H), 2.76 (s, 3H), 2.71 (s, 3H). 13C NMR (101
MHz, chloroform-d) δ: 167.6, 153.5, 151.6, 148.4, 143.0, 142.3, 138.2,
137.4, 137.0, 136.8, 129.8, 127.9, 126.4, 125.7, 125.1, 124.8, 122.8,
122.3, 121.4, 119.9, 110.1, 52.2, 15.5,15.0. m/z (+EI) calcd for
C29H23N5O2 (M)
+ 473.2, found 474.1([M] + H)+.
Synthesis of N-(3-(Dimethylamino)propyl)-2-methyl-1-(5-(3-(2-
methyl-1H-benzo[d]imidazol-6-yl)phenyl)pyridin-2-yl)-1H-benzo-
[d]imidazole-5-carboxamide (24). Starting from compound 23
(0.015 g), the same procedure used for the synthesis of tertiary
aminic tail derivatives was applied. The puriﬁcation of the crude was
obtained using a SC-X cartridge according to the “catch and release”
method described in the general section and subsequently further
puriﬁed by column chromatography (mobile phase: DCM/6 M NH3
in MeOH, 90/10, v/v), obtaining pure 24 (0.012 g, 70%) as a yellow
oil. 1H NMR (400 MHz, MeOH-d4) δ 9.08 (d, J = 2.52 Hz, 1H), 8.49
(dd, J = 2.52, 8.31 Hz, 1H), 8.21 (s, 1H), 8.05 (s, 1H), 7.73−7.88 (m,
5H), 7.62−7.69 (m, 1H), 7.54−7.62 (m, 3H), 3.53 (t, J = 6.55 Hz,
2H), 3.01−3.09 (m, 2H), 2.80 (s, 6H), 2.73 (s, 3H), 2.62 (s, 3H),
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1.99−2.08 (m, 2H). 13C NMR (101 MHz, MeOH-d4) δ: 170.9, 155.5,
150.5,149.4, 149.0, 144.5, 142.8, 139.8, 139.7, 139.3, 138.7, 138.6,
131.0, 130.9, 130.4, 128.8, 127.2, 126.7, 124.0, 122.9, 122.0, 118.9,
113.8, 111.9, 57.1, 44.0, 37.9, 26.8, 15.0, 14.5. HRMS (EI, m/z): calcd
for C33H33N7O ([M] + H)
+ 544.2819, found 544.2819.
Computational Methods. Double-strand (DS) DNAs type B
(BDNA) with 17 base pairs were generated by the NAB module of the
AMBER 12.0 package program, using the template of three diﬀerent
DNA sequences including random, AT-rich and GC-rich sequences.
The PDB ﬁle for the ligands was generated by ChemOﬃce. All the
DNA and ligands’ structures were minimized by SYBYL software
before molecular docking.
Molecular docking of the ligands to each of the generated DNA
sequences was performed by using the SMINA molecular docking
program. All parameters were kept at their default values. The grid box
was prepared to cover the full length of the DNA to allow the ligand
molecules to explore all the possible binding sites of DNA including
the major grooves and minor grooves. The pdb coordinates of the
computational models can be found in the Supporting Information.
AutoDock SMINA was used for molecular docking of the
compound 13 to the minimized crystal structure of gyrase A from S.
aureus (PDB 2XCT) for ﬁnding the binding pocket by exploring all
probable binding cavities in the protein. All the parameters were set in
their default values.
Then GOLD molecular docking was used for molecular docking of
the compound into the SMINA-located binding site for performing
ﬂexible molecular docking and determining more precise and
evaluated energy and score. On the basis of the ﬁtness function
score and ligand binding position, the best-docked pose for the
compound was selected. The less ﬁtness function score of pose,
generated using the GOLD program that has the highest GOLD
ﬁtness energy, revealed the best-docked pose for the system.
Genetic algorithm (GA) wa used in GOLD ligand docking to
examine thoroughly the ligand conformational ﬂexibility along with
partial ﬂexibility of the protein. The maximum number of runs was set
to 20 for each compound, and the default parameters were selected
(100 population size, 5 for the number of islands, 100000 number of
operations, and 2 for the niche size). Default cutoﬀ values of 2.5 Å
(dH-X) for hydrogen bonds and 4.0 Å for van-der-Waals distance were
employed. When the top solutions attained the RMSD values within
1.5 A°, the GA docking was terminated.
Eukaryotic Toxicity Determination. Cell Culture. The HeLa
(human cervical cancer) cell line was obtained from the American
Type Culture Collection. The HeLa cell line was maintained in
Dulbecco’s Modiﬁed Eagles Media (DMEM; Invitrogen) supple-
mented with fetal bovine serum (10% v/v; Invitrogen), L-glutamine (2
mM; Invitrogen), nonessential amino acids (1×; Invitrogen), and
penicillin−streptomycin (1% v/v, Invitrogen). During seeding, cells
were counted using a Neubauer hemocytometer (Assistant, Germany)
by microscopy (Nikon, USA) on a nonadherent suspension of cells
that were washed in PBS, trypsinized, centrifuged at 8 °C at 8000 rpm
for 5 min, and resuspended in a fresh medium.
MTT Assay. The cells were grown in normal cell culture conditions
at 37 °C in a 5% CO2 humidiﬁed atmosphere using an appropriate
medium. The cell count was adjusted to 105 cells/mL, and 10000 cells
were added per well. The cells were incubated for 24 h, and 1 μL of
the appropriate ligand concentrations were added to the wells in
triplicate. After 24 h of continuous exposure to each compound, the
cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Lancaster Synthesis Ltd., UK)
colorimetric assay. Absorbance was quantiﬁed by spectrophotometry
at λ = 570 nm (Envision plate reader, PerkinElmer, USA). IC50 values
were calculated by a dose−response analysis using the GraphPad
Prism software.
FRET-Based DNA Melting Assay. The oligonucleotide sequence
used for the FRET-based DNA thermal denaturation assays was
purchased from Eurogentec, Southampton, UK. Netropsin hydro-
chloride was purchased from SigmaAldrich UK. The working solution
of the oligonucleotide solution (400 nM) was prepared in a FRET
buﬀer (optimized as 50 mM potassium, 50 mM cacodylate, pH 7.4).
The oligonucleotides were annealed through heating the samples to 85
°C for 6 min followed by cooling to 25 °C and storing at this
temperature for 5 h. Annealed DNA (25 μL) and sample solution (25
μL) were added to each well of a 96-well plate (MJ Research,
Waltham, MA) and processed in a DNA Engine Opticon (MJ
Research). Fluorescence readings were taken at intervals of 0.5 °C over
the range 30−100 °C, with a constant temperature maintained for 30 s
prior to each reading. The raw data was imported into the program
Origin (Version 7.0, OringinLab Corp.), and the graphs were
smoothed using a 10-point running average and then normalized.
The determination of melting temperatures was based on values at the
maxima of the ﬁrst derivative of the smoothed melting curves using a
script. The diﬀerence between the melting temperature of each sample
and that of the blank (ΔTm) was used for comparative purposes.
Microbiological Evaluation of the Compounds. Determina-
tion of Minimum Inhibitory Concentration. MICs were determined
using the broth microdilution method as described previously.35 Cell
growth in Tryptic Soy Broth (TSB) was determined by measuring
optical density (600 nm) using a FLUOstar Omega microplate reader
(BMG Labtech). The MIC was determined as the lowest
concentration of drug at which growth was below an optical density
600 nm of 0.1 after 20 h growth. Tests were conducted in triplicate.
Where necessary, MIC determinations were carried out in the
presence of the eﬄux pump inhibitor phenylalanine-arginine β-
naphthylamide (PaβN) at 25 μg/mL. Studies with permeabilised
membranes used polymixin B nonapeptide (PMBN) at a ﬁnal
concentration of 30 μg/mL.
Time Kill Assays. Flasks of TSB were inoculated with test organisms
at a concentration of ∼106 cfu/mL in a total volume of 10 mL. The
antimicrobial agents were then added at a concentration of 4 × MIC
and incubated at 37 °C in a shaking incubator at 200 rpm. Samples
(0.1 mL) were taken from each sample 1, 2, 4, 6, and 24 h following
inoculation. The eﬀect on bacterial growth was determined using the
Miles Misra dilution method to estimate total colony forming units
(CFU) per mL. A compound was deﬁned as bactericidal if it resulted
in a loss of >3log CFU/mL. The data is representative of three
independent repeats and error bars are the standard deviation from the
mean.
DNA Gyrase Inhibition Assay. The inhibition of gyrase by the
compounds was evaluated using the S. aureus gyrase supercoiling high
throughput plate assay (no. SATRG01), obtained from Inspiralis
(Norwich, UK).36 Methods were conducted as per the manufacturer’s
instructions. Brieﬂy, compounds were incubated with gyrase enzyme
and the plasmid pNO1, which contains sequences with triplex forming
potential. Triplex forming oligonucleotides captured the negatively
supercoiled plasmids and are stained with ﬂuorescent dye (Promega
Diamond dye), which was read using a ﬂuorescent plate reader (Ex,
485 nm; Em, 520 nm) (FLUOstar Omega, BMG Labtech, Germany).
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